April 26, 2024
Market Now
Yungjin Pharm renews W181.6b contract with Japan’s Sawai
[DISCLOSURE] Yungjin Pharmaceutical (003520) announced on March 20 that it has renewed its contract with Japan’s Sawai Pharmaceutical to exclusively supply oral antibiotics.
The contract is worth 181.6 billion won (US$162.72 million), amounting to 106.7 percent of its 2015 revenue. It is valid until Dec. 31, 2021, to be automatically renewed every year without objection from either party.
By Hwang You-mee (theinvestor@heraldcorp.com)
The contract is worth 181.6 billion won (US$162.72 million), amounting to 106.7 percent of its 2015 revenue. It is valid until Dec. 31, 2021, to be automatically renewed every year without objection from either party.
By Hwang You-mee (theinvestor@heraldcorp.com)
![[KH Explains] Korean shipbuilding stocks rally: Real growth or bubble?](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2024/04/25/20240425050656_0.jpg)
![[Hello India] Hyundai Motor vows to boost 'clean mobility' in India](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2024/04/25/20240425050672_0.jpg)
